Refine by
Applications
- Solutions for Endometriosis
- Solutions for Severe but Non-Specific Symptoms
- Microbiome Therapeutics for Clinical Trials
- Affilin - Precision Targeting Technology for Protein Drug Conjugates
- Affilin - Precision Targeting Technology for Radio Conjugates
- Affilin - Precision Targeting Technology for Cellular Therapies
- Affilin - Precision Targeting Technology for Multispecific Ligands
Drug Candidates Equipment & Supplies In Finland
80 equipment items found
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
Gesynta Pharma’s drug candidate GS-073 is expected to enter clinical phase I in 2022. It is currently in the final stages of preclinical development. This project will be addressing an indication with high unmet need, which is separate from systemic ...
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
The drug candidate GS-659, which is sprung from Gesynta Pharma’s drug development platform, is currently in preclinical development phase. Project updates will be announced in due ...
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
GS-248 is Gesynta Pharma’s most advanced drug candidate, currently in clinical development as a potential treatment of systemic sclerosis. Recent clinical phase I data in healthy individuals show that GS-248 potently inhibits the production of PGE2 in a tolerable and safe manner, while increasing the observed levels of protective and vasodilatory ...
by:Oncodesign based inDijon, FRANCE
Select the best drug candidates and their biomarkers using our expertise in pharmacology! The PREDICT® technology module is a centralized manifestation of the key scientific competence of our Experimentation activity. This module is the result of more than 20 years of investment and experience that are the cornerstone of Oncodesign’s international ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our partner, Indivior, has licensed worldwide rights to our GABAB PAM program and is responsible for all development, manufacture and commercialization of any selected GABAB PAM drug candidates. Under the agreement, we are responsible for executing a research program funded by Indivior to discover novel drug candidates. Indivior ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our license agreement with Indivior provides for a funded research program, under which we have the right to select drug candidates for exclusive development in certain indications outside of SUD. We plan to develop our selected drug candidates in CMT1a, chronic cough and pain. These indications have been validated with baclofen, ...
Manufactured by:Confo Therapeutics based inGhent/Zwijnaarde, BELGIUM
Confo Therapeutics is building a pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying ...
Manufactured by:Krieger AG based inMuttenz, SWITZERLAND
Dissolution of expensive shear sensitive API's, proteins, Developing and processing small molecule and complex biologic drug candidates. Or just vacuum ...
Manufactured by:BioArctic AB based inStockholm, SWEDEN
The drug candidate ABBV-0805 is a monoclonal antibody that selectively binds and eliminates oligomers and protofibrils of alpha-synuclein. The goal is to develop a disease modifying treatment that stops or slows down disease ...
Manufactured by:3B Pharmaceuticals GmbH based inBerlin, GERMANY
Discovery and preclinical development of peptide drug candidates have been 3BP’s core competencies since the company’s inception. ...
by:STALICLA based inGeneve, SWITZERLAND
DDU validates ASD phenotype groups and drug candidates through observational studies and investigational trials. DDU combines expertise in operations, medicine, drug and clinical development, to bring STALICLA’s clinical-stage treatment options closer to ...
Manufactured by:Regeneron Pharmaceuticals Inc. based inTarrytown, NEW YORK (USA)
VelocImmune is our unique technology for producing fully human monoclonal antibodies. VelocImmune creates a multitude of optimized antibody drug candidates efficiently and directly from immunized mice. This approach overcomes the limitations of traditional platforms by rapidly creating fully human antibodies that tightly bind to therapeutic targets and avoid ...
by:Enveric Biosciences, Inc. based inNaples, FLORIDA (USA)
It streamlines pharmaceutical design by predicting ideal binding structures of molecules, manufacturing capabilities and pharmacological effects to help determine ideal drug candidates, tailored to each indication. Each of these patentable molecules is further screened to see how changes to its makeup alter its effects and whether the new molecule might be used ...
Manufactured by:Emulate based inBoston, MASSACHUSETTS (USA)
Evaluate drug candidate toxicity at clinically relevant concentrations in a co-culture human kidney model. Predicting drug-induced kidney toxicity and drug-drug interactions continues to be a challenge due to a reliance on immortalized cell line culture or animal models that do not translate to human response. ...
Manufactured by:3B Pharmaceuticals GmbH based inBerlin, GERMANY
3B Pharmaceuticals have built a drug discovery platform extending from hit identification to early clinical development. Several drug candidates developed through our platform already have been successfully administered to humans. ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our partnered drug candidate, ADX71149 is a novel orally active mGlu2 PAM for the treatment of epilepsy. Our partner, Janssen Pharmaceuticals, Inc., or Janssen, a subsidiary of Johnson & Johnson is conducting a placebo- controlled Phase 2a proof of concept clinical trial of ADX71149 in epilepsy patients since June 2021. ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
On July 29, 2020, Vivozon applied for a patent for a second pipeline, VVZ-2471, and is currently conducting non-clinical toxicity studies. VVZ-2471 is a new drug candidate for treating chronic pain including neuropathic pain. Recently, the prevention and treatment potential of drug (morphine) addiction, anxiety, and depression have also ...
Manufactured by:Nanjing Deda New Materials Technology Co., Ltd. based inNanjing, CHINA
Research and Development: PMK ethyl glycidate is utilized in pharmaceutical research to explore the synthesis of various compounds. Its stable chemical properties make it a valuable tool for scientists studying new drug candidates. ...
Manufactured by:Navigo Proteins GmbH based inHalle, GERMANY
Navigo Proteins’ Precision Targeting unit leverages its protein engineering expertise to create proprietary Affilin® molecules, harnessed to create optimized, next generation biopharmaceutical drugs in numerous fields of use. Navigo Proteins’ Affilin® platform benefits from the inherent engineerability, stability, safety, and ease of manufacturability. Our ...
Manufactured by:Bayer AG based inLeverkusen, GERMANY
However, a lot of proteins are difficult targets for SMOLs, since they do not possess defined binding sites that can be used for SMOL drug candidates and this is making them hard to drug or even “undruggable”. A new and promising approach to solve this challenge may become possible in the future. The development of new technologies ...